<DOC>
	<DOCNO>NCT00358735</DOCNO>
	<brief_summary>Evaluation safety effectiveness ActiveCare+ CECT device +/- baby dose aspirin ( 81 mg QD ) lower potential risk bleed DVT THA surgery comparison LMWH .</brief_summary>
	<brief_title>Deep Vein Thrombosis ( DVT ) Prevention Total Hip Arthroplasty : Continuous Enhanced Circulation Therapy ( CECT ) Versus Low Molecular Weight Heparin ( LMWH )</brief_title>
	<detailed_description>Patients undergoing total hip arthroplasty surgery particular risk Thromboembolic disease . To date two prophylactic modality use : mechanical ( intermittent pneumatic compression [ IPC ] ) pharmacological ( anticoagulant ) . Both effective ; however carry advantage disadvantage . The purpose study compare total hip arthroplasty ( THA ) patient safety effectiveness mobile ActiveCare CECT base prophylaxis protocol compare LMWH standard care protocol patient population . The protocol base upon CECT system primary DVT prophylaxis method ( without addition low dose baby aspirin [ 81 mg ] ) .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Adult patient ( Age &gt; 18 ) . Patient intend undergo elective primary unilateral THA surgery . Patient able willing follow instruction care surgery . Patient able willing sign institution human subject committee approve Informed Consent Form . Patient known coagulation disorder . Patient currently treat anticoagulant medication . Patient known thrombophilia Patient current sign symptom history DVT/PE . Patient uncooperative unable follow instruction . Patient currently suffer solid tumor malignancy . Patient active peptic disease . Patient know allergy baby aspirin ( 81 mg ) enoxaparin . Patient contraindication use device include patient leg gangrene , recent skin graft medical situation increase venous lymphatic return undesirable.Patient major surgery procedure within 3 month prior study surgery , patient major surgery procedure planning study period.Pregnant women.Patient participate another clinical drug trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>SAFE</keyword>
	<keyword>CECT</keyword>
	<keyword>SFT</keyword>
	<keyword>ActiveCare</keyword>
	<keyword>ActiveCare+SFT</keyword>
	<keyword>Deep Vein Thrombosis prevention</keyword>
	<keyword>Total Hip Replacement</keyword>
	<keyword>Total Hip Arthroplasty</keyword>
	<keyword>Low Molecular Weight Heparin</keyword>
	<keyword>MCS</keyword>
</DOC>